NCT06780202 Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients
| NCT ID | NCT06780202 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Emory University |
| Condition | Foot Injuries and Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 180 participants in total. It began in 2025-01-27 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries. The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes
Eligibility Criteria
Inclusion Criteria: -Emory Orthopedic patients undergoing foot and ankle surgery Exclusion Criteria: * Concurrent or significant injuries to other bones or organs * Local infections * History of alcohol or medical abuse, including prior opioid abuse * Smoking * History of severe heart disease, renal failure, liver dysfunction, active peptic ulcer disease, diabetes, rheumatoid arthritis, neurological or psychiatric diseases that could influence pain perception * Pre-existing immune suppression * Those deemed possibly non-compliant by the study team and, * All vulnerable populations (those unable to give consent, juveniles, pregnant women, prisoners, cognitively impaired and non-English speaking).
Contact & Investigator
Rishin Kadakia, MD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT06780202 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 95 Years, studying Foot Injuries and Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06780202 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06780202 currently recruiting?
Yes, NCT06780202 is actively recruiting participants. Contact the research team at jason.bariteau@emory.edu for enrollment information.
Where is the NCT06780202 trial being conducted?
This trial is being conducted at Atlanta, United States, Johns Creek, United States.
Who is sponsoring the NCT06780202 clinical trial?
NCT06780202 is sponsored by Emory University. The principal investigator is Rishin Kadakia, MD at Emory University. The trial plans to enroll 180 participants.